Switching From Tirzepatide to Retatrutide: Why There Is No Real Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Retatrutide is investigational. FormBlends does not sell or supply it. This article is educational.
• There is no outpatient switching protocol because retatrutide is not available for prescription.
• The only lawful access path is clinical trial enrollment through a TRIUMPH-program site.
• Tirzepatide half-life is ~5 days; full washout typically takes 4-5 weeks.
• Dose translation between the two drugs is not one-to-one due to different receptor pharmacology.

Direct answer

There is no clinical switching protocol from tirzepatide to retatrutide because retatrutide is not available outside clinical trials. A physician cannot prescribe it. A 503A compounding pharmacy cannot lawfully compound it for general patient use. The only lawful access is enrollment in an active TRIUMPH-program trial site, which has its own inclusion criteria, washout requirements, and titration schedule. Patients curious about switching should discuss trial enrollment and realistic expectations with their clinician.

Table of contents

1. Why this question gets asked
2. What "switching" usually means in obesity pharmacotherapy
3. The regulatory wall for retatrutide
4. What a Phase 3 trial does about prior GLP-1 use
5. Pharmacology: GIP, glucagon, and dose translation
6. Tirzepatide washout in trial enrollment
7. Weight-regain risk during a switch window
8. Trial enrollment as the lawful path
9. Contrary view: when staying on tirzepatide may be better
10. Decision framework
11. FAQ
12. Sources

Why this question gets asked

The Phase 2 retatrutide trial (Jastreboff et al., NEJM 2023) reported mean weight loss of approximately 24 percent at the 12 mg dose over 48 weeks. SURMOUNT-1 reported tirzepatide weight loss of approximately 22.5 percent at the 15 mg dose over 72 weeks. The numbers are not directly comparable (different durations, different trial designs, different populations), but the retatrutide signal suggests the possibility of greater weight loss than tirzepatide.

Patients who have plateaued on tirzepatide or who have not reached their goal weight may be curious whether retatrutide offers additional benefit. The curiosity is reasonable. The implementation is constrained by access.

What "switching" usually means in obesity pharmacotherapy

Switching between approved obesity medications generally follows one of three patterns:

• Direct substitution. Discontinuing one medication and starting the other with no washout. Reasonable when the drugs are in the same class and dose translation is well established.
• Cross-titration. Gradually reducing one while increasing the other. Reasonable for drugs with different mechanisms or significant overlap risk.
• Washout-then-restart. Discontinuing the first drug, waiting for clearance, then starting the second from the lowest dose. Reasonable when interaction risk is significant or when the new drug needs careful titration.

For GLP-1 to dual-agonist switches (e.g., semaglutide to tirzepatide), clinicians typically use direct substitution at a comparable starting point with subsequent titration. For an investigational drug like retatrutide, none of these patterns is available because there is no prescribing pathway.

The regulatory wall for retatrutide

The regulatory framework prevents retatrutide outpatient use through several mechanisms:

• No FDA approval. Retatrutide has not received FDA approval. Prescribing an unapproved drug for general patient care is outside the lawful scope of practice in the United States.
• No 503A compounding pathway. 503A compounding requires an FDA-approved active ingredient or a substance on the FDA bulks list. Retatrutide is neither.
• No 503B outsourcing. 503B outsourcing facilities can produce non-patient-specific compounds but only of FDA-approved drugs in shortage or specific listed substances. Retatrutide is neither.
• Investigational use only. An Investigational New Drug application allows use only under an IRB-approved protocol with informed consent.

This means a physician motivated to switch a patient from tirzepatide to retatrutide does not have a lawful path to do so. The only path involves referring the patient to a trial site for evaluation.

What a Phase 3 trial does about prior GLP-1 use

The TRIUMPH Phase 3 program includes specific inclusion and exclusion criteria related to prior GLP-1 or dual-agonist use. The exact criteria vary by sub-study within the program. Common patterns:

• Some sub-studies exclude recent or current GLP-1 receptor agonist use.
• Other sub-studies specifically enroll prior GLP-1 users for evaluation of switching outcomes.
• Washout periods are typically specified (e.g., 4-12 weeks from last dose).
• Specific medications may have specific washout requirements.

Patients interested in trial enrollment should review the inclusion criteria for active sites on ClinicalTrials.gov and discuss eligibility with the site coordinator.

Pharmacology: GIP, glucagon, and dose translation

Tirzepatide and retatrutide have overlapping but distinct receptor profiles:

Receptor	Tirzepatide	Retatrutide
GLP-1	Agonist	Agonist
GIP	Agonist	Agonist
Glucagon	No activity	Agonist

The glucagon receptor agonism is the new mechanism in retatrutide. Glucagon receptor stimulation increases hepatic glucose output, which would seem counterproductive for diabetes treatment, but it also increases energy expenditure, which contributes to weight loss. The net metabolic effect in the Phase 2 program was favorable, with glucose control improvement comparable to tirzepatide and greater weight loss.

Dose translation is not one-to-one. Tirzepatide doses are 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly. Retatrutide Phase 2 doses were 0.5, 1, 2, 4, 8, and 12 mg weekly with a titration lead-in. The mg values are not biologically equivalent because the molecules differ in potency and receptor selectivity profile.

Tirzepatide washout in trial enrollment

For trials that allow prior GLP-1 users, the typical washout is:

• Discontinue tirzepatide and observe the protocol-specified washout (often 4-12 weeks).
• Document weight change during washout.
• Screen for trial enrollment with labs and history.
• Initiate retatrutide at the protocol-specified starting dose with titration.

Five to six half-lives is the conventional clearance benchmark. With tirzepatide's ~5 day half-life, this translates to 4-5 weeks of washout. Some protocols specify longer washouts (8-12 weeks) to also allow for weight stabilization off the prior drug.

Weight-regain risk during a switch window

Discontinuing an effective obesity medication is typically associated with weight regain. The SURMOUNT-4 trial (Aronne et al., JAMA 2024) demonstrated that discontinuing tirzepatide after weight loss was associated with substantial regain over the subsequent year, while continued use maintained loss.

This is relevant for any switching scenario. The patient who washes out from tirzepatide and waits for trial enrollment screening is exposed to weight-regain risk during the washout. If the trial enrollment does not proceed (e.g., screen failure), the patient may be left having stopped an effective medication for no benefit.

Practical implication: patients considering trial enrollment should discuss with the trial site whether washout can begin after preliminary screening confirms likely eligibility.

Trial enrollment as the lawful path

The TRIUMPH program comprises multiple sub-studies covering obesity, diabetes, cardiovascular outcomes, and other endpoints. Enrollment process:

1. Identify active sites through ClinicalTrials.gov using "retatrutide" or "TRIUMPH" as search terms.
2. Contact the site to inquire about current enrollment status and eligibility.
3. Undergo screening visits per protocol.
4. Review and sign informed consent.
5. Random assignment, which may include placebo or active comparator arms.

Trial participation is not the same as receiving a prescription. The patient does not control dose adjustments outside the protocol, may be randomized to a non-active arm, and is subject to study procedures including labs, visits, and discontinuation rules.

Contrary view: when staying on tirzepatide may be better

Even if retatrutide eventually demonstrates greater weight loss in head-to-head Phase 3 data, several reasons may favor staying on tirzepatide for many patients:

• Tirzepatide has substantially more human safety data, with SURMOUNT-1 through SURMOUNT-4 covering tens of thousands of patient-years of exposure.
• The marginal weight-loss benefit of retatrutide over tirzepatide may not justify the loss of established efficacy in patients who are doing well on tirzepatide.
• Trial enrollment exposes patients to placebo or non-active comparator arms.
• Insurance coverage and continuity considerations favor approved drugs.

The reasonable position is that switching for the sake of switching is rarely well-motivated. Patients reaching their weight goal on tirzepatide have a strong reason to stay. Patients with substantial residual weight loss desired and no contraindication may have a reasonable case to consider trial enrollment in consultation with their clinician.

Decision framework

If you are doing well on tirzepatide:

• Continuing therapy is reasonable. Tirzepatide has substantial efficacy and safety data.
• SURMOUNT-4 data shows continued use is associated with maintained weight loss.

If you have plateaued on tirzepatide:

• Discuss with your clinician whether dose optimization, behavior modification, or adjunctive interventions are appropriate.
• Trial enrollment is a possibility but involves washout and uncertain randomization.

If you are interested in trial participation:

• ClinicalTrials.gov lists active TRIUMPH sites.
• Eligibility depends on protocol-specific criteria.

If you are considering grey-market retatrutide while staying on tirzepatide:

• Grey-market peptide quality is not verified.
• Combining two unapproved or unverified products with overlapping receptor effects carries unclear risk.

FAQ

How do you switch from tirzepatide to retatrutide? There is no outpatient switching protocol. Retatrutide is only available through clinical trial enrollment.

Can a doctor switch me? Not lawfully. A physician cannot prescribe retatrutide outside trials.

How long is the tirzepatide washout? Approximately 4-5 weeks based on the 5-day half-life. Protocol-specific washouts may be longer.

Is the dose translation one-to-one? No. The drugs have different receptor pharmacology and different titration ranges.

Why might someone want to switch? Greater weight loss in Phase 2 retatrutide data, though cross-trial comparisons require caution.

What does trial enrollment look like? Site contact, screening visits, informed consent, random assignment, and study procedures.

Can I keep tirzepatide while waiting? A clinical decision between you and your prescriber.

When will retatrutide be available? Phase 3 is ongoing; analyst projections suggest 2026-2027, but timelines can shift.

Is retatrutide FDA-approved? No. Retatrutide is investigational and not FDA-approved.

Related guides

• Switching from High-Dose Tirzepatide to Retatrutide: What the Evidence Does and Doesn't Say
• Switching From Tirzepatide to Retatrutide: What's Realistic in 2026
• Switching from Tirzepatide to Retatrutide
• Switching from Semaglutide to Retatrutide
• Is Retatrutide Better Than Tirzepatide? An Honest Cross-Trial Comparison
• Can You Switch From Tirzepatide to Retatrutide? The Honest Answer About Access

Sources

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2). NEJM. 2023;389:514-526.
2. Rosenstock J et al. Retatrutide in Type 2 Diabetes. The Lancet. 2023;402:529-544.
3. Jastreboff AM et al. Tirzepatide Once Weekly for Obesity. NEJM. 2022;387:205-216.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA. 2024.
5. Zepbound (tirzepatide) prescribing information. Eli Lilly. Revised 2024.
6. Mounjaro (tirzepatide) prescribing information. Eli Lilly. Revised 2024.
7. FDA. Investigational New Drug Application Process. 2024.
8. FDA. Compounding and the FDA: Section 503A vs 503B. 2023.
9. ClinicalTrials.gov. TRIUMPH Program Records. Accessed May 2026.
10. Eli Lilly Q4 2025 earnings presentation. TRIUMPH timeline. 2026.
11. Wilding JPH et al. Once-Weekly Semaglutide for Obesity (STEP 1). NEJM. 2021;384:989-1002.
12. Garvey WT et al. AACE/ACE Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform connecting patients with independent licensed clinicians and U.S.-licensed pharmacies. We do not manufacture, prescribe, or dispense medication.

Compounded Medication Notice. Compounded preparations from 503A pharmacies are not FDA-approved or reviewed through the FDA approval process and are not interchangeable with branded approved drugs. Retatrutide is not lawfully compoundable because it is investigational.

Results Disclaimer. Weight loss outcomes vary by individual. Cross-trial comparisons between retatrutide and tirzepatide are imperfect due to different trial designs.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Retatrutide is an investigational compound from Eli Lilly. FormBlends has no commercial relationship with Eli Lilly.